You are viewing: UK Sepsis Diagnostics Market analysis
Part of: Sepsis Diagnostics Market (Global)

The UK Sepsis Diagnostics Market was valued at $40.6 Million in 2024 and projected to reach to $54.4 Million by 2029, representing a compound annual growth rate of 6.0%. The UK sepsis diagnostics market is positioned for sustained growth through 2029, supported by NHS modernization initiatives and heightened clinical focus on sepsis management.

UK Sepsis Diagnostics Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Sepsis Diagnostics Market Trends and Insights

  • The UK market is driven by increasing sepsis incidence, rising awareness among healthcare providers, and investment in rapid diagnostic technologies within the National Health Service.
  • The UK's aging population and higher prevalence of chronic conditions are contributing to demand for faster, more accurate sepsis detection methods. In the UK, sepsis diagnostics adoption is accelerating due to regulatory support, clinical guideline updates, and integration of point-of-care testing in acute care settings.
  • The UK market benefits from strong healthcare infrastructure and government initiatives to reduce sepsis-related mortality.
  • Between 2024 and 2029, the UK is expected to see expanded deployment of molecular and immunoassay-based diagnostics across hospitals and critical care units, positioning the country as a key growth market within Europe..

Key Market Statistics

  • CAGR (2024-2029) 6.0% CAGR
  • Market Size, 2024 ~USD 40.6 Million
  • Forecast, 2029 ~USD 54.4 Million
  • Country UK

UK Sepsis Diagnostics Market Overview

Market Valuation :

The UK sepsis diagnostics market was valued at £40.6 million in 2024 and is projected to reach £54.4 million by 2029, demonstrating steady growth in this critical healthcare segment.

NHS Investment Drive :

The National Health Service is actively investing in rapid diagnostic technologies to improve sepsis detection and treatment outcomes, creating significant opportunities for diagnostic solution providers across UK healthcare facilities.

Aging Population Impact :

The UK's aging demographic profile contributes to higher sepsis prevalence, driving demand for advanced diagnostic tools in hospitals, primary care settings, and community health services nationwide.

Clinical Awareness Growth :

Increasing awareness among UK healthcare providers regarding early sepsis identification and the critical importance of rapid diagnostics is accelerating adoption of innovative testing platforms and point-of-care solutions.

UK Sepsis Diagnostics Market Dynamics

  • Healthcare providers are increasingly recognizing the economic and clinical benefits of rapid diagnostic technologies that enable faster treatment decisions and improved patient outcomes.
  • Investment in infrastructure and training across UK hospitals will continue to drive adoption of advanced diagnostic platforms.
  • The market will benefit from regulatory support for innovative diagnostics and growing integration of molecular and immunological testing methods within standard sepsis protocols..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Key Takeaways

    • The UK sepsis diagnostics market is valued at £40.6 million in 2024 and will reach £54.4 million by 2029 at a 6.0% CAGR.
    • The UK market is driven by NHS investment in rapid diagnostic technologies and clinical guideline adoption for sepsis management.
    • The UK's aging population and chronic disease burden are increasing demand for early sepsis detection solutions.
    • The UK is positioned as a key European growth market due to strong healthcare infrastructure and government sepsis mortality reduction initiatives.

    Sepsis Diagnostics Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment POINT-OF-CARE TESTS (Test Type)
    Forecast Period 2024–2029
    Growth Rate CAGR of 7% from 2024 to 2029
    Largest Segment BLOOD CULTURE (Technology)
    Market Size Base Year (Billions) ~USD 0.63 (2024)
    Revenue Forecast (Billions) ~USD 0.89 (2029)
    Segments Covered Technology, Product, Method, Pathogen Type, Type, Test Type, End User

    UK Sepsis Diagnostics Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Technology

    • Biomarkers
    • Blood Culture
    • Flow Cytometry
    • Immunoassays
    • Microfluidics
    • Molecular Diagnostics

    By Product

    • Assays & Reagent Kits
    • Blood Culture Media
    • Instruments
    • Software

    By Method

    • Automated Diagnostics
    • Conventional Diagnostics

    By Pathogen Type

    • Bacterial Sepsis
    • Fungal Sepsis
    • Other Pathogen Types

    By Type

    • Dna Sequencing
    • Gram-Negative Bacteria
    • Gram-Negative Bacterial Sepsis
    • Gram-Positive Bacteria
    • Gram-Positive Bacterial Sepsis
    • Microarrays
    • Peptide Nucleic Acid-Fluorescent In Situ Hybridization
    • Polymerase Chain Reaction

    By Test Type

    • Laboratory Tests
    • Point-Of-Care Tests

    By End User

    • Hospitals And Specialty Clinics
    • Pathology And Reference Laboratories
    • Research Laboratories, Academic Institutes, And Cros

    Target Audience

    • Diagnostic Device Manufacturers : Manufacturers seeking to expand UK market presence need detailed competitive intelligence, NHS procurement pathways, and clinical adoption trends to inform product launches and market positioning strategies.
    • Healthcare Investment Firms : Private equity and venture capital investors evaluating UK healthcare diagnostics opportunities require market sizing, growth projections, and competitive dynamics to assess investment returns and portfolio fit.
    • NHS Trust Leadership : Hospital administrators and clinical directors need market insights on diagnostic innovations, cost-effectiveness data, and implementation best practices to optimize sepsis management protocols and patient outcomes.
    • Regulatory & Compliance Consultants : Consultants advising diagnostic companies on UK market entry require detailed regulatory landscape analysis, NICE assessment criteria, and reimbursement frameworks specific to sepsis diagnostics.
    • Clinical Laboratory Directors : Laboratory managers and pathologists need information on emerging diagnostic technologies, clinical validation data, and workflow integration strategies to enhance sepsis detection capabilities within UK facilities.

    Key Companies in the UK Sepsis Diagnostics Market

    CompanyHQOwnershipStrongest segments
    CEPHEID INC.United StatesPrivate CompanyGeneXpert instruments and Xpert test cartridges,SmartCycler system and associated reagents,Collaborative and specialized assays (e.g., TB, Ebola, USPS BDS),
    NANOSPHERE, INCUnited StatesPrivate CompanyInfectious disease molecular assays,Pharmacogenetic and human genetic assays,Protein and ultra-sensitive multiplex assays,
    TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, VCM, EDC, sodium bicarbonate),Polymers and petrochemicals (PE, EVA, PVC pastes, synthetic rubber, functional polymers),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia),
    BIOMÉRIEUXFrancePublic CompanyClinical microbiology (ID/AST, blood culture, culture media),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EMAG),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
    BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (syringes, needles, vascular access, sharps, basic disposables),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related tools),Life Sciences (instruments, genomics, and reagents),Diagnostics (clinical instruments and consumables),
    T2 BIOSYSTEMS, INC.United StatesPublic CompanyT2Dx instrument,T2Candida panel,T2Bacteria panel,
    DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics – Infectious & Gastrointestinal Diseases, Hepatitis & Retroviruses,Immunodiagnostics – Endocrinology & Metabolic Disorders,Tumor Markers and Oncology Assays,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    BRUKER CORPORATIONUnited StatesPublic CompanyBSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and molecular diagnostics),BSI Nano (X-ray, AFM, electron microscopy tools),
    QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
    SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers,
    ABBOTT LABORATORIESUnited StatesPublic CompanyMedical Devices,Diagnostic Products,Nutritional Products,
    SIEMENS HEALTHINEERSGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
    QIAGEN N.V.NetherlandsPublic CompanySample technology consumables (nucleic acid stabilization/purification),Immune response and infectious disease assays (incl. TB IGRA),Oncology and sexual/reproductive health assays,
    SEEGENE, INC.South KoreaPublic CompanyRespiratory disease detection,Gastrointestinal disease detection,STI and HPV detection,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Healthcare Solutions (EMR, receipt, pharmacy, wellness),Diagnostic and Life Sciences Equipment,

    CEPHEID INC.

    Cepheid Inc. is a private molecular diagnostics company founded in 1996 in the United States with 1,700 employees. The company develops and manufactures diagnostic systems and tests.

    NANOSPHERE, INC

    Nanosphere, Inc. is a private diagnostic company founded in 1998 in the United States with 148 employees. The company focuses on molecular diagnostic technologies.

    TOSOH CORPORATION

    Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees. The company operates across multiple business segments including diagnostics and healthcare products.

    BIOMÉRIEUX

    bioMérieux is a French public company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases and industrial microbiology.

    BECTON, DICKINSON AND COMPANY

    Becton, Dickinson and Company is a United States public company founded in 1897 with 72,000 employees. The company is a global medical technology manufacturer producing diagnostic systems, devices, and reagents.

    DANAHER CORPORATION

    Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses including diagnostics and life sciences.

    T2 BIOSYSTEMS, INC.

    T2 Biosystems, Inc. is a United States public company founded in 2006 with 113 employees. The company develops rapid diagnostic technologies for infectious diseases.

    DIASORIN S.P.A.

    DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company manufactures and distributes in vitro diagnostic products.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and diagnostic solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical systems for research and diagnostics.

    QUIDELORTHO CORPORATION

    Qiagen N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.

    SYSMEX CORPORATION

    QuidelOrtho Corporation is a United States public company founded in 1979 with 6,500 employees. The company develops and manufactures rapid diagnostic tests and point-of-care solutions.

    ABBOTT LABORATORIES

    Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees. The company manufactures and sells in vitro diagnostic systems and reagents.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company develops and manufactures diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.

    QIAGEN N.V.

    QIAGEN N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.

    SEEGENE, INC.

    Seegene, Inc. is a South Korean public company founded in 2000 with 216 employees. The company develops and manufactures molecular diagnostic products and multiplex PCR technologies.

    PHC HOLDINGS CORPORATION

    PHC Holdings Corporation is a Japanese public company founded in 1948 with 8,647 employees. The company manufactures and sells medical devices and diagnostic equipment.

    Reasons to Buy this Report

    • NHS Market Penetration Strategy : Understand how to effectively position diagnostic solutions within NHS procurement frameworks and identify key decision-makers across UK hospital trusts and integrated care systems.
    • Competitive Landscape Analysis : Gain detailed insights into competing diagnostic platforms, market share distribution, and differentiation opportunities specific to the UK healthcare environment and regulatory requirements.
    • Growth Opportunity Identification : Identify high-potential segments within UK primary care, secondary care, and community settings where sepsis diagnostic adoption is accelerating and investment is concentrated.
    • Regulatory & Reimbursement Pathways : Navigate UK-specific regulatory approvals, NICE guidance, and NHS reimbursement models to accelerate market entry and optimize pricing strategies for diagnostic products.
    • Demographic & Clinical Trends : Leverage data on UK aging population patterns, sepsis incidence rates, and clinical practice evolution to forecast demand and align product development with emerging healthcare needs.

    Frequently asked questions

    What is the current size of the UK sepsis diagnostics market?

    The UK sepsis diagnostics market was valued at £40.6 million in 2024 and is expected to grow to £54.4 million by 2029.

    What is the growth rate of the UK sepsis diagnostics market?

    The UK sepsis diagnostics market is growing at a compound annual growth rate (CAGR) of 6.0% from 2024 to 2029.

    What factors are driving growth in the UK sepsis diagnostics market?

    Key drivers include NHS investment in rapid diagnostics, clinical guideline updates, an aging population, rising sepsis awareness, and government initiatives to reduce sepsis-related mortality in the UK.

    Which diagnostic technologies are most prevalent in the UK market?

    The UK market is seeing increased adoption of molecular diagnostics, immunoassay-based tests, and point-of-care testing solutions integrated across UK hospitals and critical care units.

    How does the UK market compare to other European markets?

    The UK is positioned as a key growth market within Europe due to its strong healthcare infrastructure, regulatory support, and government commitment to sepsis mortality reduction initiatives.

    RESEARCH METHODOLOGY

    This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the sepsis diagnostics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the sepsis diagnostics market. The primary sources from the demand side include OEMs, private and contract testing organizations and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

    A breakdown of the primary respondents is provided below:

    Sepsis Diagnostics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation Methodology

    In this report, the global sepsis diagnostics market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the sepsis diagnostics products business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

    Approach 1: Procedure-based estimation approach

    To calculate the global market value, installation/volume consumption of sepsis diagnostic products were calculated. This process involved the following steps:

    • Finding the total number of hospitalization at the regional and/or country-level
    • The average number of sepsis cases at the regional and/or country level
    • The average number of sepsis diagnostics tests performed per patient at the regional and/or country-level
    • The average selling price of each product type for a given year was triangulated to arrive at the market value data at the regional and/or country-level

    Sepsis Diagnostics Market Size Estimation

    Approach 2: End user-based market estimation

    During preliminary secondary research, the total sales revenue of sepsis diagnostics was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:

    • Generating a list of major customer facilities across each region and country
    • Identifying the average number of sepsis diagnostics product supplies used by major customer facilities across each product type at the regional/country level, annually
    • Identifying the percentage contribution of major customer facilities to the overall sepsis diagnostics expenditure and usage at the regional/country level, annually
    • Extrapolating the annual usage patterns for various products across major customer facilities to estimate the size of each product segment at the regional/country level, annually

    Sepsis Diagnostics Market Size Estimation

    To know about the assumptions considered for the study, Request for Free Sample Report

    Data Triangulation

    After arriving at the overall market size from the market size estimation process explained above, the global sepsis diagnostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the sepsis diagnostics market was validated using both top-down and bottom-up approaches.

    Market Definition

    Sepsis is a life-threatening condition caused by pathogen infection. It develops when chemicals released into the bloodstream to fight the infection trigger inflammatory responses throughout the body. This is a three-stage syndrome—from sepsis to severe sepsis and septic shock. Septic shock is the last stage that results in extremely low blood pressure and a lack of response to normal fluid replacement. Inflammation leads to multi-organ failure; progress to septic shock could lead to death.

    Key Market Stakeholders

    • Sepsis diagnostics reagents, instruments, blood culture media manufacturers
    • Research & academic laboratories
    • Healthcare service providers (including hospitals, reference labs, diagnostic centers, and specialty clinics)
    • Market research and consulting firms
    • Medical device suppliers, distributors, channel partners, and third-party suppliers
    • Business research and consulting service providers
    • Venture capitalists and other government funding organizations

    Objectives of the Study

    • To define, describe, and forecast the sepsis diagnostics market on the basis of on technology, product, method, pathogen type, test type, end user and region.
    • To provide detailed information regarding the major factors influencing the growth potential of the global sepsis diagnostics market (drivers, restraints, opportunities, challenges, and trends).
    • To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global sepsis diagnostics market.
    • To analyze key growth opportunities in the global sepsis diagnostics market for key stakeholders and provide details of the competitive landscape for market leaders.
    • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa (GCC Countries and Rest of MEA).
    • To profile the key players in the global sepsis diagnostics market and comprehensively analyze their market shares and core competencies.
    • To track and analyze the competitive developments undertaken in the global sepsis diagnostics market, such as agreements, expansions, and & acquisitions.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global sepsis diagnostics market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to 15)

    Geographic Analysis

    • Further breakdown of the Rest of Europe's sepsis diagnostics market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
    • Further breakdown of the Rest of Asia Pacific sepsis diagnostics market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
    • Further breakdown of the Rest of the Latin America sepsis diagnostics market into Argentina, Chile, Peru, and Colombia, among other

    Get the Full Sepsis Diagnostics Market Report

    Full forecast, segment splits, and company analysis for all Sepsis Diagnostics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status